The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies

被引:128
作者
Robertson, Chris [1 ]
Link, Carol L.
Onel, Erol
Mazzetta, Chiara
Keech, Martin
Hobbs, Richard
Fourcade, Richard
Kiemeney, Lambertus
Lee, Chongwook
Boyle, Peter
McKinlay, John B.
机构
[1] Univ Strathclyde, Glasgow G1 1XQ, Lanark, Scotland
[2] Hlth Protect Scotland, Glasgow, Lanark, Scotland
[3] New England Res Inst, Watertown, MA 02172 USA
[4] Univ Cambridge, Dept Stat, Cambridge CB2 1TN, England
[5] GlaxoSmithKline Inc, Greenford, Middx, England
[6] Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England
[7] CHU Auxerre, Serv Urol, Yonne, France
[8] Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands
[9] Seoul Natl Univ, Dept Urol, Seoul 151, South Korea
[10] Int Agcy Res Canc, F-69372 Lyon, France
关键词
LUTS; quality of life; epidemiology; comorbid illness; cultural differences;
D O I
10.1111/j.1464-410X.2007.06609.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To investigate the effect of lower urinary tract symptoms (LUTS) on quality of life (QoL) and to determine its extent across a variety of cultures, and the confounding effects of self-reported comorbidities and demographics. SUBJECTS AND METHODS Data were obtained from two population-based studies in five cities: UREPIK (Boxmeer, the Netherlands; Auxerre, France; Birmingham, UK; and Seoul, Korea) and the Boston Area Community Health (BACH) study (Boston, USA). UREPIK used stratified random samples of men aged 40-79 years. BACH used a multistage stratified cluster sample to randomly select adults aged 40-79 years. QoL was assessed using a standard Medical Outcomes Study-Short Form 12 (SF-12, mental and physical health component scores); LUTS was assessed using the International Prostate Symptom Score (IPSS). The association between QoL and IPSS, associated illnesses, and lifestyle factors was investigated using weighted regression. RESULTS The UREPIK studied 4800 men aged 40-79 years; BACH recruited 1686 men aged 40-79 years. The prevalence of LUTS, defined as an IPSS of >= 8, varied by city (P < 0.001), with Auxerre reporting a prevalence (SE) of 18.1 (1.2)%, Birmingham 25.6 (1.5)%, Boston 25.1 (1.6)%, Boxmeer 21.2 (1.3)%, and Seoul 19.0 (1.2)%. Overall, this was similar to the reported rate of high blood pressure. Severe LUTS, defined as an IPSS of >= 20, affected approximate to 3.3% of the age group; this was roughly similar to stroke (2.2%), cancer (4.5%), or heart attack (4.5%) and less than half as much as diabetes (8.6%). A 10-point increase in IPSS was associated with a 3.3 (0.3)-point reduction in SF-12 physical health component score, with the same effect in all cities (P = 0.682 for the interaction test). This was more than the physical health component score reduction caused by cancer, diabetes, or high blood pressure (2 points each), but less than stroke or heart attack (6 points). The comorbidities had no significant impact on SF-12 mental health component score (other than a heart attack, that had a 1.8-point reduction). A 10-point increase in IPSS was associated with a 3.4 (0.6)-point reduction of the mental health component score in the four western cities and a 1.4 (0.3)-point reduction in Seoul. CONCLUSIONS Increasingly severe LUTS is associated with a lower QoL. The effect of moderate LUTS on QoL physical health component score is similar to that of having diabetes, high blood pressure or cancer, while the effect of severe LUTS is similar to a heart attack or stroke. These changes were consistent across cultures. This analysis shows the magnitude and consistency of the effects of LUTS on QoL. While these patients might be seen by several types of practitioners, it is likely that urologists will be in the best position to recognize the true impact of LUTS on a patient's QoL, to be aware of the effects of therapies for LUTS on QoL, and to ensure that colleagues in other disciplines recognize the importance of these symptoms and their treatment.
引用
收藏
页码:347 / 354
页数:8
相关论文
共 27 条
[1]   Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40,000 Swedish men [J].
Andersson, SO ;
Rashidkhani, B ;
Karlberg, L ;
Wolk, A ;
Johansson, JE .
BJU INTERNATIONAL, 2004, 94 (03) :327-331
[2]  
[Anonymous], 1988, HLTH DEPRIVATION INE
[3]   THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[4]   Health status and its correlates among Dutch community-dwelling older men with and without lower urogenital tract dysfunction [J].
Blanker, MH ;
Driessen, LFC ;
Bosch, JLHR ;
Bohnen, AM ;
Thomas, S ;
Prins, A ;
Bernsen, RMD ;
Groeneveld, FPMJ .
EUROPEAN UROLOGY, 2002, 41 (06) :602-607
[5]   The relationship between lower urinary tract symptoms and health status: the UREPIK study [J].
Boyle, P ;
Robertson, C ;
Mazzetta, C ;
Keech, M ;
Hobbs, R ;
Fourcade, R ;
Kiemeney, L ;
Lee, C .
BJU INTERNATIONAL, 2003, 92 (06) :575-580
[6]  
BOYLE P, 1998, J EPIDEMIOL BIOSTAT, V3, P179
[7]  
Cochran WG., 1963, SAMPLING TECHNIQUES
[8]   Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort in clinical practice [J].
Desgrandchamps, Francois ;
Droupy, Stephane ;
Irani, Jacques ;
Saussine, Christian ;
Ccmenducci, Andrea .
BJU INTERNATIONAL, 2006, 98 (01) :83-88
[9]   Batch sampling to improve power in a community trial - Experience from the Pawtucket Heart Health Program [J].
Feldman, HA ;
McKinlay, SM ;
Niknian, M .
EVALUATION REVIEW, 1996, 20 (03) :244-274
[10]   Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project [J].
Gandek, B ;
Ware, JE ;
Aaronson, NK ;
Apolone, G ;
Bjorner, JB ;
Brazier, JE ;
Bullinger, M ;
Kaasa, S ;
Leplege, A ;
Prieto, L ;
Sullivan, M .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1171-1178